Injector High-Speed Jet Delivery for Enhanced Biofunctional Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing injectors for delivering medical liquids into the body, particularly those without needles, struggle to achieve high physiological activity due to suboptimal ejection rates and potential tissue damage, limiting the effectiveness of biofunctional substances like nucleic acids, peptides, and proteins.
Innovation Solution
An injector design with a pressurization part and ejection part capable of ejecting solutions at rates exceeding 83.3 µL/s, featuring a thin ejection part with diameters of 0.41 mm or less, allowing for high physiological activity by enhancing delivery of biofunctional substances like nucleic acids, peptides, and proteins into various internal targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a needle-equipped injector is used to slowly administer medical liquid, then the medical liquid is appropriately dispersed into the injection target, but the physiological activity and effectiveness of biofunctional substances are insufficient
Solution Approach 1:
The patent changes the ejection rate parameter from slow (conventional) to high speed (exceeding 83.3 μL/s), and modifies the ejection mechanism from gradual dispersion to high-velocity jet injection, thereby enhancing physiological activity while maintaining effective delivery
2Productivity
If a needleless injector is used to instantly push out medical liquid, then the injection process is faster, but tissue damage occurs and physiological activity is reduced
Solution Approach 1:
The patent uses a thin ejection part with specific diameter constraints (0.41 mm or less) to localize the high-velocity jet to a minimal area, reducing overall tissue damage while maintaining high ejection rates for enhanced physiological activity in the target region
3Reliability
If the ejection rate is increased to enhance physiological activity, then endocytosis is enhanced, but the ejection part requires smaller diameter which increases manufacturing difficulty
Solution Approach 1:
The patent specifies precise parameter ranges for the ejection part diameter (0.41 mm or less) and ejection rate (exceeding 83.3 μL/s) to optimize physiological activity while providing clear manufacturing guidelines that balance performance requirements with fabrication feasibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The injector achieves significantly higher physiological activity by applying shear stress for enhanced endocytosis, reducing tissue damage, and ensuring effective delivery of biofunctional substances into internal targets such as articular cavities, spleens, and livers.
Implementation Method 1
a pressurization part configured to pressurize the solution containing the biofunctional substance during actuation
Implementation Method 2
The injector achieves significantly higher physiological activity by applying shear stress for enhanced endocytosis
Data Source
Figure 1
Figure 2
Figure 3
AI summary
At least the following is provided. That is, provided is a technique by which it is possible to achieve high physiological activity when a solution containing a biofunctional substance exhibiting physiological activity in an injection target is injected into the injection target. An injector for injecting a solution containing a biofunctional substance into an injection target includes an accommodation part configured to accommodate the solution containing the biofunctional substance, a pressurization part configured to pressurize the solution containing the biofunctional substance during actuation, and an ejection part insertable into the injection target and including an inlet port configured to facilitate inflow of the solution containing the biofunctional substance from the accommodation part when the solution containing the biofunctional substance is pressurized by the pressurization part, and an outlet port configured to facilitate ejection of the flowing solution containing the biofunctional substance into the injection target. An ejection rate of the solution containing the biofunctional substance exceeds 83.3 µL/s.